bufalin has been researched along with sorafenib in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Cohen, L; Gao, Y; Gu, K; Li, HX; Meng, ZQ; Wang, P; Xu, LT; Xu, LY; Yang, PY | 1 |
Fang, T; Hu, F; Jin, X; Pan, S; Sun, X; Xu, L; Yan, H; Zhai, B; Zhao, D | 1 |
Meng, Z; Ning, Z; Wang, H; Xu, L; Zhang, C; Zhu, X | 1 |
Chi, H; Meng, Z; Wang, H; Zhang, C | 2 |
Cheng, AS; Feng, H; Gao, Y; Huang, L; Jiang, Y; Le, F; Li, M; Sun, X; Yu, DY; Yu, Z; Zhang, X; Zheng, C; Zhou, Z; Zhu, X; Zhuo, Y | 1 |
6 other study(ies) available for bufalin and sorafenib
Article | Year |
---|---|
Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
Topics: Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Bufanolides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Gene Expression Regulation, Enzymologic; Humans; Liver Neoplasms; Microscopy, Electron, Transmission; Morpholines; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
Topics: Apoptosis; Bufanolides; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2015 |
Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling.
Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Bufanolides; Cell Cycle; Cell Movement; Cell Proliferation; Cell Survival; Chick Embryo; Cytokines; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Random Allocation; Rats; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2016 |
Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bufanolides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Drug Synergism; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2018 |
Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bufanolides; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Humans; Male; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation.
Topics: Animals; beta Catenin; Bufanolides; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Glycogen Synthase Kinase 3 beta; Hepatitis B virus; Liver Neoplasms; Mice, Nude; Mice, Transgenic; Models, Biological; Phosphorylation; Proteolysis; Receptors, Androgen; Signal Transduction; Sorafenib; Trans-Activators; Viral Regulatory and Accessory Proteins | 2020 |